Merck Signs a ~$1B Pact with Janux to Develop Cancer Therapies Using T Cell Engager Technology

December 21, 2020 Auto Bot Agreement, Biotech, Develop, drug, Merck, Novel, Oncology, Signs, T-cell, technology 0

Shots:

  • Janux to receive up to $500.5M/ target as upfront and milestones along with royalties on sales of product emerges from the collaboration, making a total deal value ~$1B. Merck will fund R&D performed under the agreement
  • Merck to get an exclusive WW license to products & IP developed from the collaboration
  • The focus of the collaboration is to leverage Janux’s TRACTr technology to engineer a novel, T cell engager candidates directed against two cancer targets selected by Merck

Click here ­to­ read full press release/ article | Ref: BusinessWire | Image: BusinessWire

The post Merck Signs a ~B Pact with Janux to Develop Cancer Therapies Using T Cell Engager Technology first appeared on PharmaShots.